First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer

被引：0
|
作者：
Ohta, Katsuya [1 ,2 ]
Ikenaga, Masakazu [2 ]
Uemura, Mamoru [3 ]
Sakata, Kazuya [2 ,4 ]
Nishimura, Junichi [5 ]
Hata, Taishi [5 ]
Matsuda, Chu [5 ]
Mizushima, Tsunekazu [5 ]
Doki, Yuichiro [5 ]
Mori, Masaki [5 ]
机构：
[1] Colorectal Canc Treatment Grp MCSGO, Multictr Clin Study Grp Osaka, Osaka, Japan
[2] Osaka Univ, Dept Surg Gastroenterol, Suita, Osaka, Japan
[3] Higashiosaka City Gen Hosp, Dept Surg, Higashiosaka, Osaka, Japan
[4] Natl Hosp Org, Osaka Natl Hosp, Dept Surg, Osaka, Japan
[5] Osaka Univ, Dept Surg Gastroenterol, Suita, Osaka, Japan
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2016年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1549
引用
收藏
页码：216 / 216
页数：1
相关论文
共 50 条
  • [31] Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer
    Azadeh, Payam
    Mortazavi, Nafiseh
    Tahmasebi, Arezoo
    Kamal, Farnaz Hosseini
    Novin, Kambiz
    [J]. CHEMOTHERAPY, 2015, 61 (01) : 51 - 56
  • [32] Early magnesium modifications as a surrogate markers of efficacy of cetuximab-based anticancer treatment in KRAS wild-type colorectal cancer patients
    Vincenzi, B.
    Santini, D.
    Galluzzo, S.
    Loupakis, F.
    Correale, P.
    Addeo, R.
    Del Prete, S.
    Falcone, A.
    Francini, G.
    Tonini, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
    Bokemeyer, Carsten
    Van Cutsem, Eric
    Rougier, Philippe
    Ciardiello, Fortunato
    Heeger, Steffen
    Schlichting, Michael
    Celik, Ilhan
    Koehne, Claus-Henning
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (10) : 1466 - 1475
  • [34] CANADIAN ECONOMIC ANALYSIS OF BEVACIZUMAB, CETUXIMAB, AND PANITUMUMAB IN THE FIRST LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)
    Lawrence, D.
    Maschio, M.
    Yunger, S.
    Easaw, J.
    Aucoin, N.
    Weinstein, M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 202 - 202
  • [35] Cost-effectiveness of cetuximab, bevacizumab, and panitumumab in first-line treatment of metastatic colorectal cancer (mCRC) for patients with KRAS wild-type (wt) tumors in the United Kingdom
    Samyshkin, Y.
    Hertel, N.
    Griebsch, I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Graham, Christopher N.
    Hechmati, Guy
    Fakih, Marwan G.
    Knox, Hediyyih N.
    Maglinte, Gregory A.
    Hjelmgren, Jonas
    Barber, Beth
    Schwartzberg, Lee S.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (08) : 619 - 628
  • [37] Analysis of Kohne's prognostic index in KRAS wild-type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.
    Doi, Ayako
    Yuki, Satoshi
    Tsuji, Yasushi
    Sasaki, Takahide
    Fukushima, Hiraku
    Hatanaka, Kazuteru
    Naruse, Hirohito
    Okuda, Hiroyuki
    Kusumi, Takaya
    Fujikawa, Koshi
    Takahashi, Yasuo
    Saitoh, Soh
    Kajiura, Shinya
    Hosokawa, Ayumu
    Watanabe, Yutaka
    Yamamoto, Fumiyasu
    Kudo, Mineo
    Akakura, Nobuaki
    Sakata, Yuh
    Komatsu, Yoshito
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [38] Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study
    Liang, Yi-Hsin
    Chen, Kuo-Hsing
    Shao, Yu-Yun
    [J]. CANCER MEDICINE, 2023, 12 (14): : 15176 - 15186
  • [39] Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study
    Liang, Y.
    Shao, Y.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S272 - S273
  • [40] Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
    Baker, J. B.
    Dutta, D.
    Watson, D.
    Maddala, T.
    Munneke, B. M.
    Shak, S.
    Rowinsky, E. K.
    Xu, L-A
    Harbison, C. T.
    Clark, E. A.
    Mauro, D. J.
    Khambata-Ford, S.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 104 (03) : 488 - 495
12345